Skip to content
Screener

Crinetics Pharmaceuticals CRNX Financing Cash Flow

Financing Cash Flow at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
-$86.1M+27.0%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
-$2.04M+98.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$549.89M+812%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$87.44M+2,185,775%
XER
Xeris Biopharma Holdings, Inc.XERS
-$8.84M-182%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$12.08M+3,360%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended / March 31, 2026Three months ended / March 31, 2025
Proceeds from issuance of common stock, net of commissions380,514
Offering costs related to issuance of common stock(578)
Proceeds from exercise of stock options9,9394,437
Net cash provided by financing activities389,8754,437
Net change in cash, cash equivalents and restricted cash12,813(169,976)
Exchange rate changes in cash, cash equivalents and restricted cash(8)
Cash, cash equivalents and restricted cash - beginning of period102,336265,845
Cash, cash equivalents and restricted cash - end of period$115,141$95,869

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's financing cash flow?
Crinetics Pharmaceuticals (CRNX) reported financing cash flow of $389.88M in Q1 2026.
How has Crinetics Pharmaceuticals's financing cash flow changed year-over-year?
Crinetics Pharmaceuticals's financing cash flow increased by 8686.9% year-over-year, from $4.44M to $389.88M.
What is the long-term trend for Crinetics Pharmaceuticals's financing cash flow?
Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's financing cash flow has grown at a -36.7% compound annual growth rate (CAGR), from $252.68M to $40.61M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Crinetics Pharmaceuticals's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude